FIELD: medicine.
SUBSTANCE: invention relates to the use of a compound of the formula (I), which has high activity in inhibition of a wide range of unconditional and conditioned behavioral effects of CB1 agonists, does not have known side effects, does not cause non-specific behavioral effects, such as a sedative effect, excitability, change in spontaneous behavior, is well absorbed, is stable, and is not converted in significant amounts into following metabolites.
EFFECT: invention can be used in medicine for the treatment of disorders related to cannabinoids.
formula (I)
17 cl, 10 dwg, 8 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 3β-(Benzyloxy)-17α-METHYL-PREGN-5-EN-20-ONE FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | 2019 |
|
RU2796005C2 |
| CB1 RECEPTOR ANTAGONISTS | 2012 |
|
RU2593751C2 |
| DONECOPRID AS A NEUROPROTECTIVE AGENT IN THE TREATMENT OF NEURODEGERATIVE DISEASES | 2019 |
|
RU2800802C2 |
| COMPOSITIONS AND METHODS OF PREVENTING AND TREATING ADDICTIONS | 2008 |
|
RU2492858C2 |
| USING CANNABINOIDS COMBINED WITH ANTIPSYCHOTIC DRUG PREPARATION | 2008 |
|
RU2503448C2 |
| PERIPHERALLY RESTRICTED FAAH INHIBITORS | 2011 |
|
RU2583435C2 |
| PHARMACEUTICAL COMPOSITIONS OF THIOCHROMENOL BASED ON A HEXAHYDRO-HETEROCYCLIC COMPOUND WITH ANALGESIC EFFECT, AND METHODS FOR THEIR USE IN DOMESTIC AND FARM ANIMALS | 2022 |
|
RU2812294C2 |
| SEROTONIN 5-HT3 RECEPTOR ANTAGONISTS FOR APPLICATION IN TREATMENT OF LESIONAL VESTIBULAR DISORDERS | 2010 |
|
RU2608458C2 |
| DERIVATIVES OF PREGNENOLONE | 2013 |
|
RU2667065C2 |
| USE OF A COMPOSITION CONSISTING OF THE AMINO ACIDS GLYCINE, ARGININE, CYSTEINE AND RESVERATROL TO REDUCE THE SEVERITY OF DIABETES AND HIGH CONTENT OF FAT, CHOLESTEROL, URIC ACID, BLOOD GLUCOSE AND ACCELERATED AGING IN ANIMALS AND HUMANS | 2017 |
|
RU2749950C2 |
